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rior to DTIC alone (OR = 1.40, CI95%:1.10–1.79). Non-
interferons were ineffective (OR = 1.24, CI95%:0.93–1.65).
Interferons appeared to be effective adjunctive therapies (OR =
1.60, CI95%:1.03–2.50) with a survival of 10.5 ± 4.2 months.
However, small (older) studies produced high rates while large
(newer) studies found lower rates. CONCLUSIONS: Meta
analysis of current publications demonstrated that standard
treatment with DTIC produces response rates between 12.6 and
17.2. The addition of other treatments to DTIC offer no clinical
advantage, except possibly interferons, but incremental advan-
tages are modest at best. Studies were generally of poor quality.
Effective treatments are needed to treat advanced melanoma.
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OBJECTIVE: The aim of the present study was to develop a
patient reported outcome (PRO) instrument which would be
suitable for use in clinical practice to measure the intensity and
impact of cancer-related fatigue (CRF), as well as patients’ atti-
tudes and beliefs regarding the condition. METHODS: Ques-
tionnaire content was generated from literature review, focus
groups with oncology patients, and expert meetings with oncol-
ogists and specialists in the production of PRO instruments.
Potential items were administered to oncology patients with CRF
in a multi-center, cross-sectional, item reduction study. Patients
answered all items twice to obtain data on both item frequency
and importance using 5-point Likert-type scales. Item reduction
was performed using a combination of clinimetric (calculation
of impact score by multiplying frequency and importance scores
for each item, expert opinion) and psychometric analysis (factor
analysis, evaluation of scale internal consistency), and Item
Response Theory (IRT) techniques. RESULTS: The initial pool
of 75 items was administered to 238 cancer patients (mean age
57 years, 56% women, 30% breast cancer, 64% with metasta-
sis, 46% with anemia). The 35 items with the lowest impact
score were eliminated in clinimetric analysis; statistical analyses
eliminated a further 15 items, and 13 items were eliminated on
the basis of expert clinical opinion, supported by ﬁndings from
the IRT analysis and item-scale correlations. The ﬁnal measure
includes 12 items. Factor analysis conﬁrmed the presence of 3
dimensions: physical function (4 items), activities daily living (4
items) and beliefs/attitudes (4 items). Cronbach’s alpha values for
the overall score and individual dimensions were 0.92, 0.78,
0.85, and 0.81, respectively. CONCLUSIONS: The combination
of methods for item reduction has led to the production of a new
instrument with 12 items and 3 dimensions, which it is hoped
will be suitable to measure aspects of CRF which are important
in clinical practice.
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OBJECTIVE: A PE analysis was performed to support the reim-
bursement request of erlotinib in 2nd/3rd-line treatment of
NSCLC in The Netherlands (NL). METHODS: Erlotinib and
BSC efﬁcacy data (based on the erlotinib registration study,
BR.21) were used for this analysis. Chart reviews (n = 96) were
conducted to obtain insight into health care utilisation (HCU) of
stage IIIB/IV relapsed NSCLC. Charts from patients treated with
docetaxel (n = 24) and BSC (n = 72) in 4 general and 1 acade-
mic hospital were used. The PE analysis was performed from the
societal perspective and both outcomes and efﬁcacy results were
discounted at 4%. Ofﬁcial price lists (2004) were used and the
price of erlotinib was set at €2184/150 mg/30 tablets. PE out-
comes extrapolated to 3 years were evaluated using a Markov
health-state model, adapted for NL. Outcomes and model
assumptions were approved by an expert panel of 10 Dutch clin-
icians. RESULTS: The average treatment costs per patient in NL
were €24,939 for docetaxel, €23,436 for erlotinib, and €15,450
for BSC. Life-years gained (LYG) were 0.84 years for docetaxel
and erlotinib and 0.62 years for BSC, as per the BR.21 registra-
tion trial intent-to-treat population. The incremental cost-
effectiveness ratio (ICER) for erlotinib vs BSC was €37,059/LYG
(CI €12,621–€72,960) based on 4.3 month treatment duration.
Erlotinib dominated docetaxel in all scenarios except when an
unrealistically low docetaxel dose (110mg/cycle) was assumed.
ICERs were sensitive to variations in length/frequency of hospi-
talizations and number of outpatient visits, illustrating the eco-
nomic impact of erlotinib’s generally mild adverse event proﬁle.
Erlotinib was cost-effective vs BSC in 80% of cases using a will-
ingness-to-pay (WTP) threshold of €50,000/LYG. CONCLU-
SIONS: Treatment with erlotinib dominates docetaxel and is
cost-effective vs BSC in NL. Based on the clinical efﬁcacy and
cost-effectiveness, erlotinib has received unrestricted reimburse-
ment for relapsed NSCLC in NL without requirements for
patient stratiﬁcation.
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OBJECTIVE: To evaluate the cost-effectiveness of erlotinib com-
pared to docetaxel for treating stage III/IV relapsed NSCLC from
the UK NHS’s perspective. METHODS: A cost-utility approach
was taken; primary endpoint was cost per QALY. Baseline
patient characteristics were based on trials BR.21 (erlotinib arm)
and TAX317 (docetaxel arm). Equivalent overall survival was
assumed; any bias from this assumption was expected to favour
docetaxel. The model stratiﬁed patients into progression-free
survival (PFS), progression and death. Time in each health state
was adjusted for QoL (EQ-5D data), including the impact of
adverse events (AEs) and formulation of therapy experienced in
